Executives from Spruce Biosciences (NASDAQ:SPRB) outlined regulatory plans, clinical data highlights, and commercial considerations for the company’s lead program in Sanfilippo syndrome type B (MPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results